<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="30ba1cee-116f-089d-e063-6394a90a426f"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use CEPHALEXIN CAPSULES safely and effectively. See full prescribing information for CEPHALEXIN CAPSULES
 <br/>
      <br/>
CEPHALEXIN capsules, for oral use
 <br/>
Initial U.S. Approval: 1971
</title>
   <effectiveTime value="20250319"/>
   <setId root="28da5822-fb0b-1306-e063-6394a90a6e4c"/>
   <versionNumber value="3"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="010632300"/>
            <name>NuCare Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="010632300"/>
                        <name>NuCare Pharmaceuticals, Inc.</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C73606" displayName="repack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="68071-3740" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="30ba2720-d24f-1851-e063-6394a90ad111"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250319"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="68071-3740" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Cephalexin</name>
                        <formCode code="C25158" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Cephalexin</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="65862-018" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="35SW5USQ3G" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>D&amp;C YELLOW NO. 10</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H3R47K3TBD" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 1</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="H77VEI93A8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C YELLOW NO. 6</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="250"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="OBN7UDS42Y" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CEPHALEXIN</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="5SFF1W6677" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CEPHALEXIN ANHYDROUS</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="9" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68071-3740-9" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20241209"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="3" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="68071-3740-3" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20241209"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA065253" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20051116"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48329" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="green" xsi:type="CE">
                              <originalText>Dark Green Opaque</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="white" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CAPSULE" xsi:type="CE">
                              <originalText/>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="18" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">A;42;250;mg</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="Section_1">
               <id root="28da5822-fadf-1306-e063-6394a90a6e4c"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20211030"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Cephalexin capsules are a cephalosporin antibacterial drug indicated for the treatment of the following infections caused by susceptible isolates of designated bacteria:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Respiratory tract infection (
  
     <linkHtml href="#Section_1.1">1.1</linkHtml>)
 
    </item>
                           <item>Otitis media (
  
     <linkHtml href="#Section_1.2">1.2</linkHtml>)
 
    </item>
                           <item>Skin and skin structure infections (
  
     <linkHtml href="#Section_1.3">1.3</linkHtml>)
 
    </item>
                           <item>Bone infections (
  
     <linkHtml href="#Section_1.4">1.4</linkHtml>)
 
    </item>
                           <item>Genitourinary tract infections (
  
     <linkHtml href="#Section_1.5">1.5</linkHtml>)
 
    </item>
                        </list>
                        <br/>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of cephalexin capsules and other antibacterial drugs, cephalexin capsules should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. (
 
    <linkHtml href="#Section_1.6">1.6</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_1.1">
                     <id root="28da5822-fae0-1306-e063-6394a90a6e4c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.1 Respiratory Tract Infections</title>
                     <text>
                        <paragraph>Cephalexin capsules are indicated for the treatment of respiratory tract infections caused by susceptible isolates of
 
  <content styleCode="italics">Streptococcus pneumoniae</content>and
 
  <content styleCode="italics">Streptococcus pyogenes.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20211030"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_1.2">
                     <id root="28da5822-fae1-1306-e063-6394a90a6e4c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.2 Otitis Media</title>
                     <text>
                        <paragraph>Cephalexin capsules are indicated for the treatment of otitis media caused by susceptible isolates of
 
  <content styleCode="italics">Streptococcus pneumoniae</content>,
 
  <content styleCode="italics">Haemophilus influenzae</content>,
 
  <content styleCode="italics">Staphylococcus aureus</content>,
 
  <content styleCode="italics">Streptococcus pyogenes</content>, and
 
  <content styleCode="italics">Moraxella catarrhalis.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20211030"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_1.3">
                     <id root="28da5822-fae2-1306-e063-6394a90a6e4c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.3 Skin and Skin Structure Infections</title>
                     <text>
                        <paragraph>Cephalexin capsules are indicated for the treatment of skin and skin structure infections caused by susceptible isolates of the following Gram-positive bacteria:
 
  <content styleCode="italics">Staphylococcus aureus</content>and
 
  <content styleCode="italics">Streptococcus pyogenes</content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20211030"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_1.4">
                     <id root="28da5822-fae3-1306-e063-6394a90a6e4c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.4 Bone Infections</title>
                     <text>
                        <paragraph>Cephalexin capsules are indicated for the treatment of bone infections caused by susceptible isolates of
 
  <content styleCode="italics">Staphylococcus aureus</content>and
 
  <content styleCode="italics">Proteus mirabilis.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20211030"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_1.5">
                     <id root="28da5822-fae4-1306-e063-6394a90a6e4c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.5 Genitourinary Tract Infections</title>
                     <text>
                        <paragraph>Cephalexin capsules are indicated for the treatment of genitourinary tract infections, including acute prostatitis, caused by susceptible isolates of
 
  <content styleCode="italics">Escherichia coli</content>,
 
  <content styleCode="italics">Proteus mirabilis</content>, and
 
  <content styleCode="italics">Klebsiella pneumoniae</content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20211030"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_1.6">
                     <id root="28da5822-fae5-1306-e063-6394a90a6e4c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>1.6 Usage</title>
                     <text>
                        <paragraph>To reduce the development of drug-resistant bacteria and maintain the effectiveness of cephalexin capsules and other antibacterial drugs, cephalexin capsules should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information is available, this information should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</paragraph>
                     </text>
                     <effectiveTime value="20211030"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_2">
               <id root="28da5822-fae6-1306-e063-6394a90a6e4c"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20211030"/>
               <excerpt>
                  <highlight>
                     <text>
                        <br/>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0" width="100%">
                           <col width="50%"/>
                           <col width="50%"/>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td styleCode="Lrule Rrule" valign="top">Adults and patients at least 15 years of age 
       <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">The usual dose is 250 mg every 6 hours, but a dose of 500 mg every 12 hours may be administered (
    
       <linkHtml href="#Section_2.1">2.1</linkHtml>) 
       <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule" valign="top">Pediatric 
       <br/>  patients (over 1 
       <br/>  year of age) 
       <br/>
                                 </td>
                                 <td styleCode="Rrule" valign="top">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Otitis media: 75 to 100 mg/kg in equally divided doses every 6 hours (
      
         <linkHtml href="#Section_2.2">2.2</linkHtml>)
     
        </item>
                                       <item>All other indications: 25 to 50 mg/kg given in equally divided doses (
      
         <linkHtml href="#Section_2.2">2.2</linkHtml>)
     
        </item>
                                       <item>In severe infections: 50 to 100 mg/kg may be administered in equally divided doses (
      
         <linkHtml href="#Section_2.2">2.2</linkHtml>)
     
        </item>
                                    </list>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <br/>
                        <list listType="unordered" styleCode="Disc">
                           <item>Duration of therapy ranges from 7 to 14 days depending on the infection type and severity. (
  
     <linkHtml href="#Section_2">2</linkHtml>)
 
    </item>
                           <item>Dosage adjustment is required in patients with severe and end stage renal disease (ESRD) defined as creatinine clearance below 30 mL/min. (
  
     <linkHtml href="#Section_2.3">2.3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_2.1">
                     <id root="28da5822-fae7-1306-e063-6394a90a6e4c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Adults and Pediatric Patients at Least 15 Years of Age</title>
                     <text>
                        <paragraph>The usual dose of oral cephalexin capsules is 250 mg every 6 hours, but a dose of 500 mg every 12 hours may be administered. Treatment is administered for 7 to 14 days.</paragraph>
                        <br/>
                        <paragraph>For more severe infections larger doses of oral cephalexin capsules may be needed, up to 4 grams daily in two to four equally divided doses.</paragraph>
                     </text>
                     <effectiveTime value="20211030"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.2">
                     <id root="28da5822-fae8-1306-e063-6394a90a6e4c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Pediatric Patients (over 1 year of age)</title>
                     <text>
                        <paragraph>The recommended total daily dose of oral cephalexin capsules for pediatric patients is 25 to 50 mg/kg given in equally divided doses for 7 to 14 days. In the treatment of β-hemolytic streptococcal infections, duration of at least 10 days is recommended. In severe infections, a total daily dose of 50 to 100 mg/kg may be administered in equally divided doses.</paragraph>
                        <br/>
                        <paragraph>For the treatment of otitis media, the recommended daily dose is 75 to 100 mg/kg given in equally divided doses.</paragraph>
                     </text>
                     <effectiveTime value="20211030"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.3">
                     <id root="28da5822-fae9-1306-e063-6394a90a6e4c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Dosage Adjustments in Adult and Pediatric Patients at Least 15 Years of Age with Renal Impairment</title>
                     <text>
                        <paragraph>Administer the following dosing regimens for cephalexin capsules to patients with renal impairment
 
  <content styleCode="italics">[see</content> 
 
  <content styleCode="italics">
                              <linkHtml href="#Section_5.4">Warnings and Precautions (5.4)</linkHtml>
                           </content> and
 
  <content styleCode="italics">
                              <linkHtml href="#Section_8.6">Use in Specific Populations (8.6)</linkHtml>
                           </content>
                           <content styleCode="italics">]</content>.

 </paragraph>
                        <br/>
                        <table cellspacing="0" cellpadding="0" border="0" width="100%">
                           <caption>Table 1. Recommended Dose Regimen for Patients with Renal Impairment</caption>
                           <col width="46.72%"/>
                           <col width="53.28%"/>
                           <tfoot>
                              <tr>
                                 <td colspan="2">*There is insufficient information to make dose adjustment recommendations in patients on hemodialysis.
    
     <content styleCode="bold"/>
                                 </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="middle">
                                    <content styleCode="bold">Renal function</content>
                                    <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="middle">
                                    <content styleCode="bold">Dose regimen recommendation</content>
                                    <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="middle">Creatinine clearance &gt; 60 mL/min 
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="middle">No dose adjustment 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="middle">Creatinine clearance 30 to 59 mL/min 
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="middle">No dose adjustment; maximum daily dose should not exceed 1g 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="middle">Creatinine clearance 15 to 29 mL/min 
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="middle">250 mg, every 8 hours or every 12 hours 
     <br/>
                                 </td>
                              </tr>
                              <tr styleCode="Botrule">
                                 <td align="justify" styleCode="Lrule Rrule" valign="middle">Creatinine clearance 5 to 14 mL/min not yet on dialysis* 
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="middle">250 mg, every 24 hours 
     <br/>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="justify" styleCode="Lrule Rrule" valign="middle">Creatinine clearance 1 to 4 mL/min not yet on dialysis* 
     <br/>
                                 </td>
                                 <td align="justify" styleCode="Rrule" valign="middle">250 mg, every 48 hours or every 60 hours 
     <br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                     <effectiveTime value="20211030"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_3">
               <id root="28da5822-faea-1306-e063-6394a90a6e4c"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">250 mg capsules</content>: Dark green opaque/white size “2” hard gelatin capsule filled with off white granular powder and imprinted with “A 42” on dark green opaque cap and “250 mg” on white body with black ink.

 </paragraph>
                  <br/>
                  <paragraph>
                     <content styleCode="underline">500 mg capsules</content>: Dark green opaque/light green opaque size “0” hard gelatin capsule filled with off white granular powder and imprinted with “A 43” on dark green opaque cap and “500 mg” on light green opaque body with black ink.

 </paragraph>
               </text>
               <effectiveTime value="20211030"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Capsules: 250 mg and 500 mg (
 
    <linkHtml href="#Section_3">3</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_4">
               <id root="28da5822-faeb-1306-e063-6394a90a6e4c"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Cephalexin capsules are contraindicated in patients with known hypersensitivity to cephalexin or other members of the cephalosporin class of antibacterial drugs.</paragraph>
               </text>
               <effectiveTime value="20211030"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Patients with known hypersensitivity to cephalexin or other members of the cephalosporin class of antibacterial drugs. (
 
    <linkHtml href="#Section_4">4</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_5">
               <id root="28da5822-faec-1306-e063-6394a90a6e4c"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20211030"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Serious hypersensitivity (anaphylactic) reactions</content>: Prior to use, inquire regarding history of hypersensitivity to beta-lactam antibacterial drugs. Discontinue the drug if signs or symptoms of an allergic reaction occur and institute supportive measures. (
  
     <linkHtml href="#Section_5.1">5.1</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="italics">
                                 <content styleCode="underline">Clostridium difficile</content>
                              </content>
                              <content styleCode="underline">-associated diarrhea (CDAD</content>): Evaluate if diarrhea occurs. (
  
     <linkHtml href="#Section_5.2">5.2</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="underline">Direct Coombs’ Test Seroconversion</content>: If anemia develops during or after cephalexin therapy, evaluate for drug-induced hemolytic anemia. (
  
     <linkHtml href="#Section_5.3">5.3</linkHtml>)
 
    </item>
                           <item>
                              <content styleCode="underline">Seizure Potential</content>: Use lower dose in patients with renal impairment. (
  
     <linkHtml href="#Section_5.4">5.4</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_5.1">
                     <id root="28da5822-faed-1306-e063-6394a90a6e4c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Hypersensitivity Reactions</title>
                     <text>
                        <paragraph>Allergic reactions in the form of rash, urticaria, angioedema, anaphylaxis, erythema multiforme, Stevens-Johnson syndrome, or toxic epidermal necrolysis have been reported with the use of cephalexin. Before therapy with cephalexin is instituted, inquire whether the patient has a history of hypersensitivity reactions to cephalexin, cephalosporins, penicillins, or other drugs. Cross-hypersensitivity among beta-lactam antibacterial drugs may occur in up to 10% of patients with a history of penicillin allergy.</paragraph>
                        <br/>
                        <paragraph>If an allergic reaction to cephalexin occurs, discontinue the drug and institute appropriate treatment.</paragraph>
                     </text>
                     <effectiveTime value="20211030"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.2">
                     <id root="28da5822-faee-1306-e063-6394a90a6e4c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2

 <content styleCode="italics">Clostridium difficile</content>-Associated Diarrhea
</title>
                     <text>
                        <paragraph>
                           <content styleCode="italics">Clostridium difficile
  
   <content styleCode="bold">-</content>
                           </content>associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including cephalexin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of
 
  <content styleCode="italics">C. difficile</content>.

 </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">C. difficile</content>produces toxins A and B, which contribute to the development of CDAD. Hypertoxin-producing strains of
 
  <content styleCode="italics">C. difficile</content>cause increased morbidity and mortality, as these infections can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.

 </paragraph>
                        <br/>
                        <paragraph>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against
 
  <content styleCode="italics">C. difficile</content>may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of
 
  <content styleCode="italics">C. difficile</content>, and surgical evaluation should be instituted as clinically indicated.

 </paragraph>
                     </text>
                     <effectiveTime value="20211030"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.3">
                     <id root="28da5822-faef-1306-e063-6394a90a6e4c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Direct Coombs’ Test Seroconversion</title>
                     <text>
                        <paragraph>Positive direct Coombs’ tests have been reported during treatment with the cephalosporin antibacterial drugs including cephalexin. Acute intravascular hemolysis induced by cephalexin therapy has been reported. If anemia develops during or after cephalexin therapy, perform a diagnostic work-up for drug-induced hemolytic anemia, discontinue cephalexin and institute appropriate therapy.</paragraph>
                     </text>
                     <effectiveTime value="20211030"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.4">
                     <id root="28da5822-faf0-1306-e063-6394a90a6e4c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Seizure Potential</title>
                     <text>
                        <paragraph>Several cephalosporins have been implicated in triggering seizures, particularly in patients with renal impairment when the dosage was not reduced. If seizures occur, discontinue cephalexin. Anticonvulsant therapy can be given if clinically indicated.</paragraph>
                     </text>
                     <effectiveTime value="20211030"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.5">
                     <id root="28da5822-faf1-1306-e063-6394a90a6e4c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Prolonged Prothrombin Time</title>
                     <text>
                        <paragraph>Cephalosporins may be associated with prolonged prothrombin time. Those at risk include patients with renal or hepatic impairment, or poor nutritional state, as well as patients receiving a protracted course of antibacterial therapy, and patients receiving anticoagulant therapy. Monitor prothrombin time in patients at risk and manage as indicated.</paragraph>
                     </text>
                     <effectiveTime value="20211030"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.6">
                     <id root="28da5822-faf2-1306-e063-6394a90a6e4c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Development of Drug-Resistant Bacteria</title>
                     <text>
                        <paragraph>Prescribing cephalexin in the absence of a proven or strongly suspected bacterial infection is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.</paragraph>
                        <br/>
                        <paragraph>Prolonged use of cephalexin may result in the overgrowth of nonsusceptible organisms. Careful observation of the patient is essential. If superinfection occurs during therapy, appropriate measures should be taken.</paragraph>
                     </text>
                     <effectiveTime value="20211030"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_6">
               <id root="28da5822-faf3-1306-e063-6394a90a6e4c"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following serious events are described in greater detail in the Warning and Precautions section:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Hypersensitivity reactions
  
   <content styleCode="italics">[see
   
    <linkHtml href="#Section_5.1">Warning and Precautions (5.1)</linkHtml>]
  
   </content>
                     </item>
                     <item>
                        <content styleCode="italics">Clostridium difficile</content>-associated diarrhea
  
   <content styleCode="italics">[see
   
    <linkHtml href="#Section_5.2">Warnings and Precautions (5.2)</linkHtml>]
  
   </content>
                     </item>
                     <item>Direct Coombs’ Test Seroconversion
  
   <content styleCode="italics">[see
   
    <linkHtml href="#Section_5.3">Warnings and Precautions (5.3)</linkHtml>]
  
   </content>
                     </item>
                     <item>Seizure Potential
  
   <content styleCode="italics">[see
   
    <linkHtml href="#Section_5.4">Warnings and Precautions (5.4)</linkHtml>]
  
   </content>
                     </item>
                     <item>Effect on Prothrombin Activity
  
   <content styleCode="italics">[see
   
    <linkHtml href="#Section_5.5">Warnings and Precautions (5.5)</linkHtml>]
  
   </content>
                     </item>
                     <item>Development of Drug-Resistant Bacteria
  
   <content styleCode="italics">[see
   
    <linkHtml href="#Section_5.6">Warnings and Precautions (5.6)</linkHtml>]
  
   </content>
                     </item>
                  </list>
                  <br/>
               </text>
               <effectiveTime value="20211030"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions associated with cephalexin include diarrhea, nausea, vomiting, dyspepsia and abdominal pain
 
    <content styleCode="bold">.</content>(
 
    <linkHtml href="#Section_6">6</linkHtml>)

   </paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <br/>  To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .
    </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_6.1">
                     <id root="28da5822-faf4-1306-e063-6394a90a6e4c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</paragraph>
                        <br/>
                        <paragraph>In clinical trials, the most frequent adverse reaction was diarrhea. Nausea and vomiting, dyspepsia, gastritis, and abdominal pain have also occurred. As with penicillins and other cephalosporins, transient hepatitis and cholestatic jaundice have been reported.</paragraph>
                        <br/>
                        <paragraph>Other reactions have included hypersensitivity reactions, genital and anal pruritus, genital candidiasis, vaginitis and vaginal discharge, dizziness, fatigue, headache, agitation, confusion, hallucinations, arthralgia, arthritis, and joint disorder. Reversible interstitial nephritis has been reported. Eosinophilia, neutropenia, thrombocytopenia, hemolytic anemia, and slight elevations in aspartate transaminase (AST) and alanine transaminase (ALT) have been reported.</paragraph>
                        <br/>
                        <paragraph>In addition to the adverse reactions listed above that have been observed in patients treated with cephalexin, the following adverse reactions and other altered laboratory tests have been reported for cephalosporin class antibacterial drugs:</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">Other Adverse Reactions</content>: Fever, colitis, aplastic anemia, hemorrhage, renal dysfunction, and toxic nephropathy.

 </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">Altered Laboratory Tests</content>: Prolonged prothrombin time, increased blood urea nitrogen (BUN), increased creatinine, elevated alkaline phosphatase, elevated bilirubin, elevated lactate dehydrogenase (LDH), pancytopenia, leukopenia, and agranulocytosis.  

 </paragraph>
                     </text>
                     <effectiveTime value="20211030"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_7">
               <id root="28da5822-faf5-1306-e063-6394a90a6e4c"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20211030"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Metformin: increased metformin concentrations. Monitor for hypoglycemia. (
  
     <linkHtml href="#Section_7.1">7.1</linkHtml>)
 
    </item>
                           <item>Probenecid-The renal excretion of cephalexin is inhibited by probenecid. Co-administration of probenecid with cephalexin is not recommended. (
  
     <linkHtml href="#Section_7.2">7.2</linkHtml>)
 
    </item>
                           <item>Administration of cephalexin may result in a false-positive reaction  glucose in the urine. (
  
     <linkHtml href="#Section_7.3">7.3</linkHtml>)
 
    </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_7.1">
                     <id root="28da5822-faf6-1306-e063-6394a90a6e4c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Metformin</title>
                     <text>
                        <paragraph>Administration of cephalexin with metformin results in increased plasma metformin concentrations and decreased renal clearance of metformin.</paragraph>
                        <br/>
                        <paragraph>Careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking cephalexin and metformin
 
  <content styleCode="italics">[see
  
   <linkHtml href="#Section_12.3">Clinical Pharmacology (12.3)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20211030"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.2">
                     <id root="28da5822-faf7-1306-e063-6394a90a6e4c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 Probenecid</title>
                     <text>
                        <paragraph>The renal excretion of cephalexin is inhibited by probenecid. Co-administration of probenecid with cephalexin is not recommended.</paragraph>
                     </text>
                     <effectiveTime value="20211030"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.3">
                     <id root="28da5822-faf8-1306-e063-6394a90a6e4c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Interaction with Laboratory or Diagnostic Testing</title>
                     <text>
                        <paragraph>A false-positive reaction may occur when testing for the presence of glucose in the urine using Benedict’s solution or Fehling’s solution.</paragraph>
                     </text>
                     <effectiveTime value="20211030"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_8">
               <id root="28da5822-faf9-1306-e063-6394a90a6e4c"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20211030"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Renal Impairment: Monitor patients longer for toxicity and drug interactions due to delayed clearance. (8.6)</item>
                        </list>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_8.1">
                     <id root="28da5822-fafa-1306-e063-6394a90a6e4c"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary 
   <br/>
                           </content>
                        </paragraph>
                        <paragraph>Available data from published epidemiologic studies and pharmacovigilance case reports over several decades with cephalosporin use, including cephalexin use in pregnant women have not established drug-associated risks of major birth defects, miscarriage, or adverse maternal or fetal outcomes
 
  <content styleCode="italics">(see Data)</content>.

 </paragraph>
                        <br/>
                        <paragraph>Animal reproduction studies with mice and rats using oral doses of cephalexin that are 0.6- and 1.2-times the maximum recommended human dose (MRHD) based on body surface area during organogenesis revealed no evidence of harm to the fetus
 
  <content styleCode="italics">(see Data).</content>
                        </paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">Human Data</content>
                        </paragraph>
                        <paragraph>While available studies cannot definitively establish the absence of risk, published data from epidemiologic studies and postmarketing case reports over several decades have not identified a consistent association with cephalosporin use, including cephalexin, during pregnancy, and major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Available studies have methodologic limitations, including small sample size, retrospective data collection, and inconsistent comparator groups.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>In animal reproduction studies, pregnant mice and rats administered oral cephalexin doses of 250 or 500 mg/kg/day (approximately 0.6 and 1.2 times the MRHD) based on body surface area, respectively during the period of organogenesis showed no adverse effects on embryofetal development.</paragraph>
                        <br/>
                        <paragraph>In a pre-and post-natal developmental toxicity study, pregnant rats that received oral doses of 250 or 500 mg/kg/day of cephalexin from Day 15 of pregnancy to litter Day 21 showed no adverse effects on parturition, litter size, or growth of offspring.</paragraph>
                     </text>
                     <effectiveTime value="20211030"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.2">
                     <id root="28da5822-fafb-1306-e063-6394a90a6e4c"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary 
   <br/>
                           </content>
                           <br/>  Data from a published clinical lactation study reports that cephalexin is present in human milk. The Relative Infant Dose (RID) is considered to be &lt;1% of the maternal weight adjusted dose. There are no data on the effects of cephalexin on the breastfed child or on milk production.

 </paragraph>
                        <br/>
                        <paragraph>The development of health benefits of breastfeeding should be considered along with the mother’s clinical need for cephalexin and any potential adverse effects on the breastfed child from cephalexin or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20211030"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.4">
                     <id root="28da5822-fafc-1306-e063-6394a90a6e4c"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of cephalexin in pediatric patients was established in clinical trials for the dosages described in the dosage and administration section
 
  <content styleCode="italics">[see
  
   <linkHtml href="#Section_2.2">Dosage and Administration (2.2)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20211030"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.5">
                     <id root="28da5822-fafd-1306-e063-6394a90a6e4c"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Of the 701 subjects in 3 published clinical studies of cephalexin, 433 (62%) were 65 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients.</paragraph>
                        <br/>
                        <paragraph>This drug is substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection
 
  <content styleCode="italics">[see
  
   <linkHtml href="#Section_5.4">Warnings and Precautions (5.4)</linkHtml>].
 
  </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20211030"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.6">
                     <id root="28da5822-fafe-1306-e063-6394a90a6e4c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>Cephalexin should be administered with careful monitoring in the presence of renal impairment (creatinine clearance &lt; 30 mL/min, with or without dialysis). Under such conditions, careful clinical observation and laboratory studies renal function monitoring should be conducted because safe dosage may be lower than that usually recommended
 
  <content styleCode="italics">[see
  
   <linkHtml href="#Section_2.3">Dosage and Administration (2.3)</linkHtml>]
 
  </content>. Monitor patients longer for toxicity and drug interactions due to delayed clearance.

 </paragraph>
                     </text>
                     <effectiveTime value="20211030"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_10">
               <id root="28da5822-faff-1306-e063-6394a90a6e4c"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Symptoms of oral overdose may include nausea, vomiting, epigastric distress, diarrhea, and hematuria. In the event of an overdose, institute general supportive measures.</paragraph>
                  <br/>
                  <paragraph>Forced diuresis, peritoneal dialysis, hemodialysis, or charcoal hemoperfusion have not been established as beneficial for an overdose of cephalexin.</paragraph>
               </text>
               <effectiveTime value="20211030"/>
            </section>
         </component>
         <component>
            <section ID="Section_11">
               <id root="28da5822-fb00-1306-e063-6394a90a6e4c"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Cephalexin capsules, USP is a semisynthetic cephalosporin antibacterial drug intended for oral administration. It is 7-(D-α-Amino-α-phenylacetamido)-3-methyl-3-cephem-4-carboxylic acid monohydrate. Cephalexin has the molecular formula C
 
  <sub>16</sub>H
 
  <sub>17</sub>N
 
  <sub>3</sub>O
 
  <sub>4</sub>S•H
 
  <sub>2</sub>O and the molecular weight is 365.41.

 </paragraph>
                  <br/>
                  <paragraph>Cephalexin has the following structural formula: 
  <br/>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <br/>
                  <br/>
                  <paragraph>Each capsule contains cephalexin monohydrate equivalent to 250 mg or 500 mg of cephalexin. The capsules also contain the following inactive ingredients: microcrystalline cellulose, croscarmellose sodium, D&amp;C Yellow No. 10, FD&amp;C Blue No. 1, FD&amp;C Yellow No. 6, gelatin, magnesium stearate, titanium dioxide, and sodium lauryl sulfate.</paragraph>
               </text>
               <effectiveTime value="20211030"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cephalexin-str.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_12">
               <id root="28da5822-fb01-1306-e063-6394a90a6e4c"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20211030"/>
               <component>
                  <section ID="Section_12.1">
                     <id root="28da5822-fb02-1306-e063-6394a90a6e4c"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Cephalexin is a cephalosporin antibacterial drug
 
  <content styleCode="italics">[see
  
   <linkHtml href="#Section_12.4">Microbiology (12.4)</linkHtml>]
 
  </content>.

 </paragraph>
                     </text>
                     <effectiveTime value="20211030"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.3">
                     <id root="28da5822-fb03-1306-e063-6394a90a6e4c"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Absorption:</content>
                        </paragraph>
                        <br/>
                        <paragraph>Cephalexin is acid stable and may be given without regard to meals. Following doses of 250 mg, 500 mg, and 1 g, average peak serum levels of approximately 9, 18, and 32 mcg/mL, respectively, were obtained at 1 hour. Serum levels were detectable 6 hours after administration (at a level of detection of 0.2 mcg/mL).</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Distribution:</content>
                        </paragraph>
                        <br/>
                        <paragraph>Cephalexin is approximately 10% to 15% bound to plasma proteins.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Excretion:</content>
                        </paragraph>
                        <br/>
                        <paragraph>Cephalexin is excreted in the urine by glomerular filtration and tubular secretion. Studies showed that over 90% of the drug was excreted unchanged in the urine within 8 hours. During this period, peak urine concentrations following the 250 mg, 500 mg, and 1 g doses were approximately 1000, 2200, and 5000 mcg/mL respectively.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Drug Interactions: 
   <br/>
                           </content>
                           <br/>  In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean C
 
  <sub>max</sub>and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%. No information is available about the interaction of cephalexin and metformin following multiple doses of either drug.

 </paragraph>
                     </text>
                     <effectiveTime value="20211030"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.4">
                     <id root="28da5822-fb04-1306-e063-6394a90a6e4c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>12.4 Microbiology</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Mechanism of Action</content>
                        </paragraph>
                        <br/>
                        <paragraph>Cephalexin is a bactericidal agent that acts by the inhibition of bacterial cell-wall synthesis.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Resistance</content>
                        </paragraph>
                        <br/>
                        <paragraph>Methicillin-resistant staphylococci and most isolates of enterococci are resistant to cephalexin. Cephalexin is not active against most isolates of
 
  <content styleCode="italics">Enterobacter</content>spp.,
 
  <content styleCode="italics">Morganella morganii</content>, and
 
  <content styleCode="italics">Proteus vulgaris</content>. Cephalexin has no activity against
 
  <content styleCode="italics">Pseudomonas</content>spp., or
 
  <content styleCode="italics">Acinetobacter calcoaceticus</content>. Penicillin-resistant
 
  <content styleCode="italics">Streptococcus pneumoniae</content>is usually cross-resistant to beta-lactam antibacterial drugs.

 </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Antimicrobial Activity</content>
                        </paragraph>
                        <br/>
                        <paragraph>Cephalexin has been shown to be active against most isolates of the following bacteria both 
 
  <content styleCode="italics">in vitro</content>and in clinical infections [
 
  <content styleCode="italics">see
  
   <linkHtml href="#Section_1">Indications and Usage (1)</linkHtml>
                           </content>].

 </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Gram-positive bacteria</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Staphylococcus aureus</content>(methicillin-susceptible isolates only)

 </paragraph>
                        <paragraph>
                           <content styleCode="italics">Streptococcus pneumoniae</content>(penicillin-susceptible isolates)

 </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Gram-negative bacteria</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Escherichia coli</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Haemophilus influenzae</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Klebsiella pneumoniae</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Moraxella catarrhalis</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Proteus mirabilis</content>
                        </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="bold">Susceptibility Testing 
   <br/>
                              <br/>
                           </content>For specific information regarding susceptibility test interpretive criteria and associated test methods and quality control standards recognized by FDA for this drug, please see: https://www.fda.gov/STIC.

 </paragraph>
                     </text>
                     <effectiveTime value="20211030"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_17">
               <id root="30ba26ab-53d1-95c8-e063-6294a90aac8b"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">
                        <content styleCode="bold">250 mg Capsule</content>
                     </content>
                  </paragraph>
                  <paragraph>Dark green opaque/white size “2” hard gelatin capsule filled with off white granular powder and imprinted with “A 42” on dark green opaque cap and “250 mg” on white body with black ink.</paragraph>
                  <paragraph>Bottles of 3 NDC 68071-3740-3</paragraph>
                  <paragraph/>
                  <paragraph>Bottles of 9 NDC 68071-3740-9</paragraph>
               </text>
               <effectiveTime value="20241209"/>
            </section>
         </component>
         <component>
            <section ID="Section_13">
               <id root="28da5822-fb05-1306-e063-6394a90a6e4c"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20211030"/>
               <component>
                  <section ID="Section_13.1">
                     <id root="28da5822-fb06-1306-e063-6394a90a6e4c"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Lifetime studies in animals have not been performed to evaluate the carcinogenic potential of cephalexin. Tests to determine the mutagenic potential of cephalexin have not been performed. In male and female rats, fertility and reproductive performance were not affected by cephalexin oral doses up to 1.5 times the highest recommended human dose based upon body surface area.</paragraph>
                     </text>
                     <effectiveTime value="20211030"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_16">
               <id root="28da5822-fb08-1306-e063-6394a90a6e4c"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph> 
 
  <content styleCode="underline">Allergic Reactions</content>
                  </paragraph>
                  <paragraph>
                     <br/>  Advise patients that allergic reactions, including serious allergic reactions, could occur and that serious reactions require immediate treatment. Ask the patient about any previous hypersensitivity reactions to cephalexin, other beta-lactams (including cephalosporins) or other allergens (5.1) 
  <br/>   
 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Diarrhea 
   <br/>
                     </content>
                     <br/>  Advise patients that diarrhea is a common problem caused by antibacterial drugs and usually resolves when the drug is discontinued. Sometimes, frequent watery or bloody diarrhea may occur and may be a sign of a more serious intestinal infection. If severe watery or bloody diarrhea develops, advise patients to contact their healthcare provider. 
  <br/>   

 </paragraph>
                  <paragraph>
                     <content styleCode="underline">Antibacterial Resistance 
   <br/>
                     </content>
                     <br/>  Counsel patients that antibacterial drugs including cephalexin, should only be used to treat bacterial infections. They do not treat viral infections (e.g., the common cold). When cephalexin is prescribed to treat a bacterial infection, tell patients that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by cephalexin or other antibacterial drugs in the future. 
  <br/>   

 </paragraph>
                  <paragraph>Distributed by: 
  <br/>
                     <content styleCode="bold">Aurobindo Pharma USA, Inc. 
   <br/>
                     </content>279 Princeton-Hightstown Road 
  <br/>  East Windsor, NJ 08520 
  <br/>
                     <br/>  Manufactured by: 
  <br/>
                     <content styleCode="bold">Aurobindo Pharma Limited 
   <br/>
                     </content>Hyderabad-500 032, India 
  <br/>
                     <br/>  Revised: 10/2021

 </paragraph>
                  <br/>
               </text>
               <effectiveTime value="20211030"/>
            </section>
         </component>
         <component>
            <section ID="Section_18">
               <id root="2a093d20-99c2-4fe2-e063-6394a90a0774"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL- PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>
                     <renderMultiMedia referencedObject="img_28da6ed0-1938-1e6c-e063-6294a90a306f"/>
                  </paragraph>
               </text>
               <effectiveTime value="20241209"/>
               <component>
                  <observationMedia ID="img_28da6ed0-1938-1e6c-e063-6294a90a306f">
                     <text>pdp</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="68071-3740-9.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>